Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPirfenidone
说明： Antifibrotic agent; regulates cytokine levels in vivo
化学名： 5-methyl-1-phenyl-2(1H)-pyridinone
纯度： ≥99% (HPLC)
生物活性 for Pirfenidone
Pirfenidone is a antifibrotic agent, effective in models of pulmonary and lung fibrosis. Inhibits collagen production and fibroblast proliferation. Regulates cytokine levels following oral administration in vivo. Potent scavenger of free radicals and inhibitor of lipid peroxidation.
技术数据 for Pirfenidone
| 分子量 | 185.23 |
| 公式 | C12H11NO |
| 储存 | Store at RT |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 53179-13-8 |
| PubChem ID | 40632 |
| InChI Key | ISWRGOKTTBVCFA-UHFFFAOYSA-N |
| Smiles | CC1=CN(C(=O)C=C1)C1=CC=CC=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for Pirfenidone
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| water | 3.7 | 20 |
制备储备液 for Pirfenidone
以下数据基于产品分子量 185.23。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.2 mM | 26.99 mL | 134.97 mL | 269.93 mL |
| 1 mM | 5.4 mL | 26.99 mL | 53.99 mL |
| 2 mM | 2.7 mL | 13.5 mL | 26.99 mL |
| 10 mM | 0.54 mL | 2.7 mL | 5.4 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for Pirfenidone
参考文献 for Pirfenidone
参考文献是支持产品生物活性的出版物。
Iyer et al (1999) Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleo. hamster model of lung fibrosis. J.Pharmacol.Exp.Ther. 289 211 PMID: 10087006
Kehrer and Margolin (1997) Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol.Lett. 90 125 PMID: 9067480
Mei et al (2005) Protection of pirfenidone against an early phase of oleic acid-induced acute lung injury in rats. J.Pharmacol.Exp.Ther. 313 379 PMID: 15608079
Oku et al (2002) Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock. Eur.J.Pharmacol. 446 167 PMID: 12098599
If you know of a relevant reference for Pirfenidone, please let us know.
按标靶查看相关产品
关键词: Pirfenidone, Pirfenidone supplier, Antifibrotic, agent, regulates, cytokine, levels, vivo, TNF-α, TNF-alpha, Interleukins, Tumor, Necrosis, Factor-α, Factor-alpha, Cytokines, Cytokine, NF-κB, NF-kappaB, Signaling, Signalling, esbriet, 1093, Tocris Bioscience
1 篇 Pirfenidone 的引用文献
引用文献是使用了 Tocris 产品的出版物。 Pirfenidone 的部分引用包括：
Griffiths (2018) Anti-fibrotic effects of CXCR4-targeting i-body AD-114 in preclinical models of pulmonary fibrosis. Sci Rep 8 3212 PMID: 29453386
您是否知道使用了 Tocris Pirfenidone 的优秀论文？ 请告知我们.
Pirfenidone 的评论
目前没有该产品的评论。 Be the first to review Pirfenidone and earn rewards!
Have you used Pirfenidone?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.